Pharmacologic Management of Isolated Low High-Density Lipoprotein Syndrome
Bermudez et al. - Torcetrapib, a cholesteryl esters transfer protein inhibitor, represented a hope to raise this lipoprotein; however, all clinical trials on this drug had ceased after ILLUMINATE, RADIANCE and ERASE trials had recorded an increase in mortality, rates of myocardial infarction, angina, and heart failure. In the near future, drugs as [beta]-glucans, Apo-A1 mimetic peptides, and ACAT inhibitors, are the new promises to treat this condition. [more...]
|
|
|
